Introduction
============

Retroperitoneal tumours are classified according to their origin into mesodermal, neurogenic, and germinative tumours ([@r1]). Liposarcomas are of mesodermal origin and are derived from fat tissue. Primary liposarcomas in the retroperitoneum are aggressive and rare with an incidence rate of 1 per 2.5 million ([@r2]). If they are diagnosed early, localized tumours can be successfully treated with surgical resection and possibly adjuvant oncological therapy, according to the histology ([@r3]). In such cases, the five-year survival for high grade tumours in the spermatic cord in adults is approximately 75% ([@r1],[@r4]). However, lifelong follow-up is recommended after treatment, as late recurrences have been recorded ([@r5]).

Case presentation
=================

A 69-year-old man was referred to the Department of Urology, Roskilde Hospital on suspicion of malignancy because of increasing scrotal swelling in spite of antibiotic treatment.

On clinical examination a painless process along the spermatic cord was palpated. It was free of the testicle and did not stretch into the inguinal canal. A computerized tomography (CT) scan was performed and this revealed a 4.4 cm tumour distally in the inguinal canal stretching toward the epididymis. Biochemically, alpha-foetoprotein, s-human chorionic gonadotropin and lactate dehydrogenase levels were all within normal limits.

The patient was admitted for further observation of the swollen area, but his clinical condition worsened and the pain and swelling increased rapidly. A surgical exploration of the inguinal area and scrotum was performed. Peroperatively a firm 6 cm × 6 cm process in the spermatic cord was found. To ensure negative margins, a wide resection was performed ([*Figure 1*](#f1){ref-type="fig"}). Histological examination showed the presence of lipoblast cells and the analysis for classification determinant 34 (CD34) showed positive result suggesting a liposarcoma. An analysis for mouse double minute 2 homolog (MDM2) and antigen Ki-67 test was done, both of them were positive resulting in the diagnose of a de-differentiated liposarcoma in the spermatic cord ([*Figure 2*](#f2){ref-type="fig"}).
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A thoracic postoperative CT scan showed no signs of metastasis and the patient was referred to a highly specialised multidisciplinary team to receive adjuvant radiation therapy. The total follow-up period is currently 8 months with no signs of recurrence.

Discussion
==========

Liposarcomas in the spermatic cord were first described in 1952, and there are only approximately 200 cases described in the literature ([@r6],[@r7]).

Due to the high fat content, it can be difficult to distinguish lipomas from liposarcomas with ultrasound and CT scans. Therefore, the preferred method for the diagnosis of these fatty structures is magnetic resonance imaging (MRI). For differential diagnostic purposes, the cancer markers alpha fetoprotein, s-hCG, and lactate dehydrogenase are used to identify possible germ cell tumours.

The histological diagnosis of liposarcomas is divided into three categories according to their cytogenetic characteristics in either well-differentiated or de-differentiated: (I) myxoid and (II) round cell tumours often have high incidence and are satisfactorily treated with resection with a wide margin; (III) pleomorphic liposarcomas are low-differentiated and highly malignant and the treatment is radical resection.

There is no gold standard for the treatment of liposarcomas in the spermatic cord, however there is evidence to support that radical surgery is the most important factor in the treatment. Provided the tumour is well-differentiated and defined, it is possible to give adjuvant radiotherapy in order to minimize the risk for local recurrence, however there is no evidence that this improves the prognosis. The patients should attend lifelong follow-up with clinical evaluation and CT scan of the thorax and abdomen, since recurrence of liposarcomas has been seen up to 15 years after the initial treatment ([@r5]).
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